Yokohama, Japan

Taro Uchiyama

This inventor holds 1 USPTO granted patent. Top assignee: Shiseido Company, Limited. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Taro Uchiyama. Retrieved from https://idiyas.com/inventor/taro-uchiyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Taro Uchiyama: Innovator in Glomerulonephritis Treatment

Introduction

Taro Uchiyama is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of medicine, particularly in the development of treatments for glomerulonephritis. His innovative approach has led to the creation of a unique medicine that addresses this serious health condition.

Latest Patents

Uchiyama holds 1 patent for his invention titled "Glomerulonephritis inhibitor." This medicine is effective in inhibiting glomerulonephritis and contains docosahexaenoic acid or its derivatives, such as salts, esters, or amides. This breakthrough has the potential to improve the quality of life for patients suffering from this condition.

Career Highlights

Taro Uchiyama is associated with Shiseido Company, Limited, where he continues to work on innovative solutions in the medical field. His dedication to research and development has positioned him as a key figure in the fight against glomerulonephritis.

Collaborations

Uchiyama has collaborated with esteemed colleagues, including Toshiji Kanayama and Isao Yanagisawa. Their combined expertise has contributed to the advancement of medical treatments and innovations.

Conclusion

Taro Uchiyama's work in developing a glomerulonephritis inhibitor showcases his commitment to medical innovation. His contributions are paving the way for new treatments that can significantly impact patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…